急性髓系白血病中乳腺癌耐药蛋白基因表达与临床意义*

摘要

Objective To explore the expression and prognostic value of breast cancer resistance protein (BCRP) gene in acute myeloid leukemia (AML). Methods Real time quantitative polymerase chain reaction (RT-PCR) method was performed to detect the mRNA of BCRP in AML group (n=60) and non-hematologic malignancy group ( =20). The difference in the expression of both groups was studied and its correla-tion with clinical effect was analyzed. Results The gene expression level in the AML patients was sta-tistically higher than that in the control group (P<0.01). Significant difference was found among the newly-diagnosed AML group, the relapsed AML group and the complete remission (CR) AML group and the control group ( <0.01). The gene expression level was different in different disease stages with the highest lev-el in the relapsed group and the lowest in the complete-remission group. Conclusions BCRP gene expression increases in AML patients. The expression level of gene can be a useful biomarker for evaluation of AML progression, and may be an independent risk factor of AML.%目的：研究急性髓细胞白血病（AML）患者乳腺癌耐药蛋白（BCRP）基因的表达以及在预后判断中的意义。方法构建实时定量PCR检测BCRP基因表达的技术，定量检测20例初治组AML患者、20例完全缓解组AML患者及20例难治复发组AML患者基因的表达水平，分析其在AML患者BCRP和非血液系统恶性肿瘤患者中的差异及与临床疗效的关系。结果急性髓系白血病患者中BCRP的表达高于对照组（<0.01），初治组、完全缓解组、难治复发组的表达均存在差异（<0.01），其中难治复发组表达最高，初治组次之，完全缓解组最低。结论基因在急性髓系白血病患者中表达增高，BCRP的表达水平可能是疾病进展的重要标志，可能是AML的独立危险因素。